Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Possible Hereditary Link Between Ovarian and Testicular Cancers Observed

March 20, 2018
By Dave Levitan
Article

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A registry study suggests that there may be a familial association between ovarian and testicular cancers. In the study, men with testicular cancer were more likely to have a mother with ovarian cancer compared with men with other malignancies.

Testicular germ cell tumors (TGCT) are the most common malignancies among American men aged 15 to 44 years; family history of TGCT has been well established as a risk factor for these tumors. “Although familial TGCT studies have yet to characterize TGCT syndromic patterns, a biologically plausible link between TGCT and ovarian germ cell tumors has been posited,” wrote study authors led by Kirsten B. Moysich, PhD, of the Roswell Park Comprehensive Cancer Center in Buffalo.

The investigators conducted a study using data from the Familial Ovarian Cancer Registry to test for associations between ovarian cancer and TGCT. They included a total of 2,636 families with multiple cases of ovarian cancer. Results were published in Cancer Epidemiology.

The cohort contained 34 men with testicular cancer, and 2,894 men with non-testicular cancers. Of those 34 men, 24 had mothers with known ovarian cancer status, and 10 mothers (41.67%) had ovarian cancer while 14 did not. This meant that the men with testicular cancer were significantly more likely to have a mother with ovarian cancer compared with the men with other malignancies, with an odds ratio (OR) of 3.32 (95% CI, 1.46–7.55; P = .004). The same was true for having a sister with ovarian cancer, though this did not reach significance, with an OR of 1.66 (95% CI, 0.87–3.15; P = .124); of the 43 sisters of men with testicular cancer with known ovarian cancer status, 14 (32.56%) had ovarian cancer.

The men in the registry with testicular cancer fathered 13 daughters, but these daughters were either too young to be at risk for ovarian cancer, or lacked adequate follow-up. Four of 16 maternal grandmothers had ovarian cancer (25%), and none of 9 paternal grandmothers with known status had the malignancy.

The mechanism for this connection may involve X-chromosome–linked susceptibility genes, the authors wrote. “While the observed absence of ovarian cancer in paternal grandmothers of men with testicular cancer is consistent with X-linked transmission, analyses were limited by small sample sizes and X-linkage could not be conclusively established,” they noted.

An attempt to update the registry and improve the family histories and collection of biospecimens is underway, specifically in families with multiple cases of ovarian cancer as well as at least one case of testicular cancer. “These analyses may provide insight into the etiology of transmission patterns of both cancers and expose novel gene targets for prevention and therapy,” the authors wrote.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Related Content

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
September 16th 2025
Podcast

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

Russ Conroy
September 16th 2025
Article

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
September 16th 2025
Podcast

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
September 16th 2025
Article

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.

Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer

Russ Conroy
September 16th 2025
Article
Related Content

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
September 16th 2025
Podcast

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

Russ Conroy
September 16th 2025
Article

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
September 16th 2025
Podcast

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
September 16th 2025
Article

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.

Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer

Russ Conroy
September 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.